Physician profile
David Wayne Davis
NPI 1134609704
$1,162.35
in general payments reported to CMS, 2019-2025
19 companies · $22.40 in 2025
The $22.40 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $261 · 2022: $609 · 2023: $204 · 2024: $65.22 · 2025: $22.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $239.03 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $210.58 | 2021-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.52 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $57.00 | 2022-2023 | Rexulti |
| Abbvie INC. | $55.64 | 2022-2023 | |
| Corium, LLC | $52.01 | 2022 | |
| Lilly USA, LLC | $48.55 | 2021-2024 | Mounjaro |
| Exact Sciences Corporation | $46.36 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $44.48 | 2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $42.56 | 2021-2022 | |
| Glaxosmithkline, LLC. | $27.81 | 2021-2022 | |
| Amgen INC. | $22.76 | 2021 | |
| Smith+Nephew, INC. | $22.40 | 2025 | Collagenase Santyl |
| Xeris Pharmaceuticals, INC. | $19.42 | 2021 | |
| Becton, Dickinson and Company | $19.27 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $18.55 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.18 | 2022 | |
| Agile Therapeutics, INC. | $14.31 | 2022 | |
| Exeltis, USA INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.